Increased FoxP3 expression among CD4+ lymphocytes has been described in patients treated with etanercept, a fusion protein acting as TNF inhibitor [94], but these data were not confirmed in other studies evaluating the in vivo effects of this compound on RA Treg cells [90, 91]. This evidence concerns the gene CD4 and rheumatoid arthritis.